Incidence of Mortality, Acute Kidney Injury and Graft Loss in Adult Kidney Transplant Recipients with Coronavirus Disease 2019: Systematic Review and Meta-Analysis.
Jia-Jin ChenGeorge KuoTao-Han LeeHuang-Yu YangHsin-Hsu WuKun-Hua TuYa-Chung TianPublished in: Journal of clinical medicine (2021)
The adverse impact of Coronavirus disease 2019 (COVID-19) on kidney function has been reported since the global pandemic. The burden of COVID-19 on kidney transplant recipients, however, has not been systematically analyzed. A systematic review and meta-analysis with a random-effect model was conducted to explore the rate of mortality, intensive care unit admission, invasive mechanical ventilation, acute kidney injury, kidney replacement therapy and graft loss in the adult kidney transplant population with COVID-19. Sensitivity analysis, subgroup analysis and meta-regression were also performed. Results: we demonstrated a pooled mortality rate of 21% (95% CI: 19-23%), an intensive care unit admission rate of 26% (95% CI: 22-31%), an invasive ventilation rate among those who required intensive care unit care of 72% (95% CI: 62-81%), an acute kidney injury rate of 44% (95% CI: 39-49%), a kidney replacement therapy rate of 12% (95% CI: 9-15%), and a graft loss rate of 8% (95% CI: 5-15%) in kidney transplant recipients with COVID-19. The meta-regression indicated that advancing age is associated with higher mortality; every increase in age by 10 years was associated with an increased mortality rate of 3.7%. Regional differences in outcome were also detected. Further studies focused on treatments and risk factor identification are needed.
Keyphrases
- coronavirus disease
- intensive care unit
- mechanical ventilation
- acute kidney injury
- replacement therapy
- sars cov
- risk factors
- cardiovascular events
- respiratory syndrome coronavirus
- cardiac surgery
- emergency department
- acute respiratory distress syndrome
- randomized controlled trial
- palliative care
- cardiovascular disease
- extracorporeal membrane oxygenation
- respiratory failure
- chronic pain
- phase iii
- affordable care act